Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study

Main Article Content

Michael Cork
Diamant Thaçi
Lawrence Eichenfield
Peter Arkwright
Zhen Chen
Mohamed Kamal
John O'Malley
Ashish Bansal

Keywords

Atopic Dermatitis, Biologic, Dupilumab, Pediatrics, Safety, Efficacy

Abstract

Abstract not available.

References

1. Wollenberg A, et al. J Eur Acad Dermatol Venereol 2016;30:729-47.

2. Sidbury R, et al. J Am Acad Dermatol 2014;71:327-49.

3. Ring J, et al. J Eur Acad Dermatol Venereol. 2012;26:1176-93.

4. Drucker AM, et al. Br J Dermatol. 2018; 178:768-75.

5. Totri CR, et al. J Am Acad Dermatol. 2017; 76:281-5.

6. Macdonald LE, et al. Proc Natl Acad Sci U S A. 2014;111:5147-52.

7. Murphy AJ, et al. Proc Natl Acad Sci U S A. 2014;111:5153-8.

8. Cork MJ, et al. Br J Dermatol. 2020;182:85-96.